Australia’s drug regulator, the Therapeutic Goods Administration (TGA), now calls for feedback on whether the agency should allow the use of repurposed, off-label ivermectin as an antiviral regimen against SARS-CoV-2, the virus behind COVID-19. TrialSite reported last September that TGA took their gloves off with physicians prescribing the drug off-label, formally placing a national prohibition on off-label prescribing of the drug to all general practitioners (GPs). This was a comparable move for what TGA did with hydroxychloroquine in 2020. The agency limited ivermectin access for COVID-19 to specialists. This media reported that this action didn’t occur in a vacuum, rather it involved the citing of lack of evidence, but in fact, comparable actions were occurring in multiple developed economies. Was this a carefully coordinated and orchestrated government action to stop all treatments other than those the government deemed acceptable? This media pondered: was the underlying mission to stop any activity that interrupted the mass vaccination program?

Now, those GP restrictions are under review again with the TGA Advisory Committee on Medicines Scheduling addressing the topic in November.

https://www.trialsitenews.com/a/australias-tga-to-reconsider-ivermectin-gp-restrictions-in-november-0423231b